Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-1
2024-511361-11-00Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of brigimadlin in Liposarcoma (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free survival (PFS). Started Sep 2024; status: completed.
02
Drugs
brigimadlin
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on 2024-511361-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511361-11-00.